A Phase 2 interventional study of Naltrexone and Acetaminophen and Naltrexone and Acetaminophen-High Dose in Migraine With or Without Aura, sponsored by Allodynic Therapeutics, Inc. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-14.
Sponsored by Allodynic Therapeutics, Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing acetaminophen in Migraine Disorders — 1 open to participants now, 1 under way, none of them phase 3. Acetaminophen · Migraine Disorders.
Among the 15 studies testing acetaminophen in Migraine Disorders, this one is the 10th largest by enrollment, is one of 4 that started in 2017, is one of 4 in phase 2, and was the 7th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →1 of the 15 studies testing acetaminophen in Migraine Disorders is open now, in 1 country. Recruiting first, the newest first:
University of Monastir · Sites in Tunisia
Ages 18+
By country, each count listing its studies:
Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 4 · Phase 4 5
First in 1998; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 92 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 200 across the 15 interventional studies. Of the 12 that completed or were terminated, 4 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 15 have an industry lead sponsor. The 9 most frequent:
Allodynic Therapeutics, Inc is the lead sponsor of 7 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Allodynic Therapeutics, Inc has 5 studies filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 15 studies testing acetaminophen in Migraine Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study consists of a screening visit, out-patient treatment of a moderate or severe migraine attack with a single dose of the study medication within 8 weeks, and End-of-Study Visit 2-7 days after dosing.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients take one capsule containing naltrexone and one capsule containing acetaminophen together for a qualifying migraine
Drug: Naltrexone and Acetaminophen
Patient take one capsule containing naltrexone (high dose) and one capsule containing acetaminophen together for a qualifying migraine
Drug: Naltrexone and Acetaminophen-High Dose
Patient take one capsule containing naltrexone and one capsule containing placebo together for a qualifying migraine
Drug: Naltrexone Alone (regular dose)
Patient take one capsule containing naltrexone and one capsule containing placebo together for a qualifying migraine
Drug: Acetaminophen Alone
Patient take two capsule containing placebo together for a qualifying migraine
Drug: Matching Placebo
Drug pages: Naltrexone · Acetaminophen
Naltrexone plus acetaminophen
Naltrexon (high dose) plus acetaminophen
Naltrexone Alone plus Placebo
Acetaminophen Alone plus Placebo
Two Placebo capsules
% of patients reporting no headache pain.
Self-reported headache pain on a four-point Likert scale.
Time frame: 2 hours post-dose
% of patients having absence of most bothersome migraine-associated symptom (MBS).
MBS was prospectively identified at baseline. Self-reported MBS as present or absent.
Time frame: 2 hours post-dose
% of patients who have "sustained pain freedom"
Defined as having no headache pain at 2 hours after dose, with no use of rescue medication and no relapse of headache pain within 24 hours after administration of the investigational drug.
Time frame: 24-hour post-dose.
% of patients having absence of nausea, photophobia, phonophobia, and neck/shoulder pain
Self-reported the current status of their associated symptom as present or absent.
Time frame: 24-hour post-dose.
% of patients who used rescue medications
Time frame: 2-24 hours
% of patients who had headache pain relapse.
Defined as the return of headache of any severity within 48 hours after administration of the investigational drug, when the patient was pain-free at 2 hours after the administration of the investigational drug.
Time frame: 2-48 hours
% of patients who experienced adverse events
treatment related Adverse Events
Time frame: 48 hours
Plan to share: No
Ran from Feb 2017 to primary completion in Feb 2018, 11 months.
Of 43 industry-sponsored phase 2 interventional studies under Migraine Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 11 months is close to that.
Counting every sponsor, half of 73 studies reached it within 15 months; a quarter within 11 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Naltrexone · Acetaminophen
Allodynic Therapeutics, Inc